首页|Henan University Reports Findings in Personalized Medicine (Prognostic value of CDKN2A in head and neck squamous cell carcinoma via pathomics and machine learni ng)
Henan University Reports Findings in Personalized Medicine (Prognostic value of CDKN2A in head and neck squamous cell carcinoma via pathomics and machine learni ng)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-New research on Drugs and Therapies-Personalized Medicine is the subject of a report. According to news reporting fr om Kaifeng, People's Republic of China, by NewsRx journalists, research stated, "This study aims to enhance the prognosis prediction of Head and Neck Squamous C ell Carcinoma (HNSCC) by employing artificial intelligence (AI) to analyse CDKN2 A gene expression from pathology images, directly correlating with patient outco mes. Our approach introduces a novel AI-driven pathomics framework, delineating a more precise relationship between CDKN2A expression and survival rates compare d to previous studies." The news correspondents obtained a quote from the research from Henan University , "Utilizing 475 HNSCC cases from the TCGA database, we stratified patients into high-risk and low-risk groups based on CDKN2A expression thresholds. Through pa thomics analysis of 271 cases with available slides, we extracted 465 distinctiv e features to construct a Gradient Boosting Machine (GBM) model. This model was then employed to compute Pathomics scores (PS), predicting CDKN2A expression lev els with validation for accuracy and pathway association analysis. Our study dem onstrates a significant correlation between higher CDKN2A expression and improve d median overall survival (66.73 months for high expression vs. 42.97 months for low expression, p = 0.013), establishing CDKN2A's prognostic value. The pathomi c model exhibited exceptional predictive accuracy (training AUC: 0.806; validati on AUC: 0.710) and identified a strong link between higher Pathomics scores and cell cycle activation pathways. Validation through tissue microarray corroborate d the predictive capacity of our model. Confirming CDKN2A as a crucial prognosti c marker in HNSCC, this study advances the existing literature by implementing a n AI-driven pathomics analysis for gene expression evaluation."
KaifengPeople's Republic of ChinaAsi aCancerCarcinomasCyborgsDrugs and TherapiesEmerging TechnologiesHead and Neck CancerHealth and MedicineMachine LearningOncologyPersonalized MedicinePersonalized TherapySquamous Cell Carcinoma
NETL
NSTL
